Planting Fidelity's seeds

Why Fidelity decided to help create neurodegenerative play Denali

Fidelity Biosciences Research Initiative has helped create a neurodegenerative disease company that could serve as a repository for the discoveries stemming from seed investments in academia that FBRI has quietly been making for the past six years. The newco, Denali Therapeutics Inc., debuted last week with $217 million.

"While Fidelity Biosciences is disease-agnostic, we're mission driven and are focused on neurodegeneration," said Stacie Weninger, executive director of FBRI. "We find and fund everything from basic research in academia to early stage company research before a VC would get interested."

FBRI is a division of Fidelity Biosciences, a venture firm that itself is a division of the financial conglomerate Fidelity Investments. In academia, FBRI provides what Weninger terms "catalyst funding," or a couple of years of financial support designed to get a project to the stage where it can attract early academic grant support or even traditional venture funding.

FBRI's investment in the neurodegeneration field

Read the full 1566 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE